ORKAMBI Drug Patent Profile

« Back to Dashboard

Which patents cover Orkambi, and when can generic versions of Orkambi launch?

Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are twenty-three patents protecting this drug.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; lumacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Orkambi

Orkambi was eligible for patent challenges on July 2, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 20, 2031. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ORKAMBI

US Patents:	23
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	19
Patent Applications:	205
Drug Prices:	Drug price information for ORKAMBI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORKAMBI
What excipients (inactive ingredients) are in ORKAMBI?	ORKAMBI excipients list
DailyMed Link:	ORKAMBI at DailyMed

See drug prices for ORKAMBI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ORKAMBI

NDA:

211358

Dosage:

GRANULE;ORAL

NDA:

206038

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ORKAMBI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Qanatpharma Canada LTD	Phase 1
Children's Hospital Medical Center, Cincinnati	N/A
University of North Carolina	Early Phase 1

See all ORKAMBI clinical trials

Pharmacology for ORKAMBI

Drug Class	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Mechanism of Action	Chloride Channel Activation Potentiators Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 2C9 Inducers Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors P-Glycoprotein Inducers P-Glycoprotein Inhibitors

US Patents and Regulatory Information for ORKAMBI

ORKAMBI is protected by twenty-three US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-002	Aug 7, 2018		RX	Yes	Yes
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-001	Jul 2, 2015		RX	Yes	Yes					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-001	Aug 7, 2018		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-001	Aug 7, 2018		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-002	Sep 28, 2016		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-001	Jul 2, 2015		RX	Yes	Yes					Y

EU/EMA Drug Approvals for ORKAMBI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vertex Pharmaceuticals (Ireland) Limited	Orkambi	lumacaftor, ivacaftor	EMEA/H/C/003954Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene.	Authorised	no	no	no	2015-11-19

International Patents for ORKAMBI

When does loss-of-exclusivity occur for ORKAMBI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Norway

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORKAMBI around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	081069
Argentina	081760
Australia	2011237494
Australia	2011237601
Brazil	112012026255
Brazil	112012026257

Supplementary Protection Certificates for ORKAMBI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1773816	C300748	Netherlands		PRODUCT NAME: N-(5-HYDROXY-2,4-DI-TERT-BUTYL-; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725
1773816	CA 2015 00038	Denmark		PRODUCT NAME: IVACAFTOR, N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF; REG. NO/DATE: EU/1/12/782/001-002 20120723
1773816	PA2015028	Lithuania		PRODUCT NAME: IVACAFTORUM; REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120723
1773816	C20150028 00162	Estonia		PRODUCT NAME: IVAKAFTOOR;REG NO/DATE: EU/1/12/782/001-002 25.07.2012
1773816	1590036-8	Sweden		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/12/782/001, 2012-07-25; DEN 2025-05-21 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD: 1590036-8,1690018-5, 1490016-1
1773816	15C0045	France		PRODUCT NAME: IVACAFTOR, OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725

Orkambi Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: October 2, 2026

Orkambi, Vertex Pharmaceuticals’ fixed-dose combination of lumacaftor and ivacaftor, has moved from a major cystic fibrosis product to a declining legacy franchise. U.S. sales peaked before the broad adoption of Trikafta, then fell sharply as patients switched to Vertex’s newer CFTR modulator. The commercial decline reflects product substitution more than loss of cystic fibrosis demand.

Orkambi retains value in patients who cannot use newer modulators, in younger age groups where treatment eligibility has expanded over time, and in markets with slower reimbursement or regulatory uptake. Its principal risks are continued migration to Trikafta or Kaftrio, generic entry after relevant patent barriers weaken, and pricing pressure in international markets.

What is Orkambi and how does it compete in cystic fibrosis?

Orkambi combines lumacaftor, a CFTR corrector, with ivacaftor, a CFTR potentiator. It is approved for patients with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene.

The product was designed to address the underlying CFTR defect rather than treat only pulmonary symptoms. Its commercial market is therefore defined by genotype, age, treatment eligibility, reimbursement and access to competing CFTR modulators.

Product	Active ingredients	Primary eligible population	Commercial position
Kalydeco	Ivacaftor	Specific gating and residual-function mutations	First-generation targeted CFTR modulator
Orkambi	Lumacaftor/ivacaftor	F508del homozygous patients	Earlier-generation corrector-potentiator combination
Symdeko	Tezacaftor/ivacaftor	Broader mutation coverage than Orkambi	Intermediate-generation product
Trikafta/Kaftrio	Elexacaftor/tezacaftor/ivacaftor	Broadest major CFTR modulator coverage	Current Vertex franchise leader

The U.S. Food and Drug Administration approved Orkambi in July 2015 for patients aged 12 and older. FDA later expanded the indication to younger patients, including children aged 2 to 5, following earlier approval for the 6-to-11 age group.[1]

How has Orkambi revenue changed over time?

Orkambi revenue declined after the launch of Symdeko and collapsed after the introduction of Trikafta. Vertex’s annual reports identify product switching as the central driver.

Year	Orkambi revenue trend	Main commercial driver
2015	Initial launch year	U.S. launch and rapid adoption
2016	Approximately $1.4 billion	Broad uptake in F508del homozygous patients
2017	Approximately $1.0 billion	Early substitution by Symdeko and reimbursement pressure
2018	Approximately $1.0 billion	Continued competition from Symdeko
2019	Approximately $0.8 billion	Trikafta launch in the United States
2020	Approximately $0.5 billion	Rapid conversion to Trikafta
2021	Approximately $0.4 billion	Continued patient migration
2022	Approximately $0.3 billion	Legacy-patient concentration
2023	Below $0.2 billion	Mature residual demand
2024	Approximately $0.1 billion	Trikafta dominance and ongoing erosion

The precise yearly amounts depend on Vertex’s reporting presentation and currency effects, but the direction is clear: Orkambi became a declining product once newer Vertex regimens offered broader mutation coverage and generally more favorable clinical performance.

Vertex’s cystic fibrosis franchise expanded even as Orkambi declined. Trikafta and Kaftrio became the principal revenue engine, offsetting the reduction in Orkambi, Symdeko and Kalydeco sales.[2-5]

Why did Orkambi sales fall?

The decline has four primary causes:

1. Trikafta offers substantially broader mutation coverage.
2. Trikafta became the preferred regimen for many eligible patients.
3. Patients already receiving Orkambi could be switched to newer treatment.
4. Payer and physician decisions increasingly favored the newest Vertex regimen.

Orkambi’s commercial exposure is therefore linked to the installed base of patients who remain on older therapy, cannot tolerate newer treatment, lack access to Trikafta or Kaftrio, or live in markets where reimbursement changes more slowly.

When did Orkambi lose exclusivity?

Orkambi’s regulatory exclusivity began with its U.S. approval in 2015. The principal statutory periods were:

Exclusivity type	Relevant timing	Commercial effect
New chemical entity exclusivity	Approximately July 2015 to July 2020	Blocked submission of an ANDA relying on Orkambi’s reference product during the five-year period
Pediatric exclusivity	Six-month extension attached to qualifying exclusivity periods	Extended applicable regulatory protection
Orphan-drug exclusivity	Potentially relevant because cystic fibrosis is a rare disease	Limited approval of the same drug for the same disease during the applicable period
Patent protection	Extends beyond regulatory exclusivity	Determines the practical timing of generic launch

Regulatory exclusivity does not establish the final generic-entry date. Small-molecule generic manufacturers can challenge patents through Paragraph IV certifications, and the reference sponsor can seek a 30-month stay under the Hatch-Waxman framework. The effective market-entry date depends on patent litigation, settlement terms, court decisions and any applicable pediatric or other regulatory extensions.

What patents protect Orkambi?

Orkambi is protected by a combination of patents covering lumacaftor, ivacaftor, pharmaceutical compositions, fixed-dose combinations and methods of treating cystic fibrosis.

The relevant U.S. patent categories include:

Patent category	Protected subject matter	Strategic purpose
Lumacaftor compound patents	The corrector molecule and related chemical matter	Base active-ingredient protection
Ivacaftor compound patents	The potentiator molecule	Background protection shared with other Vertex products
Combination patents	Lumacaftor plus ivacaftor	Direct protection for Orkambi-type treatment
Formulation patents	Tablets, dosage forms and excipients	Limits substitutable formulations
Method-of-use patents	Treatment of F508del homozygous cystic fibrosis	Supports infringement claims based on labeled use
Manufacturing patents	Processes for producing active ingredients or intermediates	Raises supply-chain and development barriers

The FDA Orange Book is the principal U.S. source for patents listed against the reference product. Because Orange Book entries can change through delisting, expiration, pediatric extensions and court outcomes, the applicable patent set must be assessed as of the proposed generic filing and launch date.[6]

Orkambi’s strongest remaining protection is not necessarily the original compound patent. Combination, formulation and method-of-use patents can remain commercially relevant after the earliest molecule patents have expired. Their practical value depends on claim scope, enforceability, design-around options and the percentage of prescriptions written for the patented indication.

How strong is the Orkambi patent estate?

The estate is weaker than the estate supporting Trikafta for three reasons:

• Orkambi is an older product with a longer commercial history.
• Its key active ingredients and combination architecture were disclosed earlier.
• The market has already shifted to a newer product with more valuable and later-expiring patent protection.

The estate still creates meaningful generic-entry risk because a generic manufacturer must address several patent families, not only the earliest compound patent. A Paragraph IV challenger may seek to invalidate or design around selected claims rather than attack the entire estate.

What is the Orange Book status of Orkambi?

Orkambi is an FDA-approved small-molecule reference product and is treated under the ANDA framework rather than the biosimilar pathway. Its Orange Book listings are relevant to:

• Abbreviated new drug applications for lumacaftor/ivacaftor;
• Paragraph IV certifications;
• Potential 30-month litigation stays;
• Substitution and therapeutic-equivalence analysis;
• Patent expiration and launch planning.

There is no biosimilar pathway for Orkambi because biosimilars apply to biologic products. A competitive product would be a generic equivalent or an alternative CFTR modulator, depending on its regulatory route.

Which companies are challenging Orkambi exclusivity?

Public commercial competition has been dominated by Vertex’s own products rather than by a branded rival. Symdeko first displaced part of the Orkambi population, and Trikafta later became the principal replacement.

The generic competitive field is different. Potential challengers would likely include large generic companies with experience in complex oral products and patent litigation. The relevant risk is not limited to a named Paragraph IV filer. A generic manufacturer can submit an ANDA confidentially and disclose the challenge only after the reference sponsor receives the certification.

No biosimilar companies are relevant to Orkambi. The competitive issue is generic lumacaftor/ivacaftor entry and substitution by other CFTR modulators.

What patent litigation and settlements affect Orkambi?

The commercial importance of Orkambi litigation has diminished as the product’s revenue base has contracted. A successful generic launch would affect a smaller residual market than it would have affected before Trikafta.

The key litigation questions are:

1. Whether the generic product infringes listed combination or formulation claims.
2. Whether the relevant patents are valid and enforceable.
3. Whether the generic applicant can carve out patented methods of use.
4. Whether a settlement delays entry and preserves a defined launch date.
5. Whether the generic can obtain therapeutic equivalence and substitution status.

Settlement economics are less attractive for both parties when the reference product has already lost most of its patients to an internal successor. Vertex has a stronger incentive to protect Orkambi where a generic could accelerate erosion of residual revenue or create pricing pressure across the CF portfolio. A generic company has less incentive to incur prolonged litigation expense if the addressable market is already small.

What generic launch scenarios exist for Orkambi?

Scenario 1: Delayed entry after patent expiry

A generic launches after the relevant Orange Book patents expire. This is the cleanest path but may produce limited value because most eligible patients are already treated with Trikafta or Kaftrio.

Scenario 2: Paragraph IV launch after settlement

The generic and Vertex agree to an entry date before the latest listed patent expiration. The settlement could include a delayed launch, supply terms or restrictions on commercial activity.

Scenario 3: At-risk launch

The generic launches before final resolution of patent litigation after determining that the patents are invalid, not infringed or unenforceable. This creates potential damages exposure if Vertex prevails.

Scenario 4: Carve-out launch

The generic removes a patented indication or method from its labeling. This approach may reduce patent exposure but can limit substitution and physician uptake.

Scenario 5: No meaningful generic launch

A generic may obtain approval but remain commercially inactive because of low residual demand, manufacturing complexity, limited payer savings or the dominance of Trikafta.

The fifth scenario is credible for an aging specialty product. Approval alone does not guarantee a commercially material launch.

What manufacturing and intellectual-property barriers affect Orkambi?

Lumacaftor/ivacaftor is an oral small-molecule combination, but generic development still requires more than reproducing the active ingredients. Key barriers include:

• Demonstrating bioequivalence for a fixed-dose combination;
• Matching dissolution and release characteristics;
• Controlling polymorph, impurity and degradation profiles;
• Establishing reliable supply of both active ingredients;
• Reproducing tablet manufacturing at commercial scale;
• Managing separate patent positions for lumacaftor, ivacaftor and the combination;
• Addressing any formulation or process claims that restrict design-around options.

These barriers are lower than those for biologics but higher than those for a simple immediate-release single-ingredient tablet.

How does Orkambi compare with Trikafta?

Metric	Orkambi	Trikafta/Kaftrio
Regimen	Two components	Three components
CFTR activity	Corrector plus potentiator	Two correctors plus potentiator
Mutation coverage	Concentrated in F508del homozygous patients	Much broader eligible population
Commercial stage	Mature, declining	Core growth franchise
Switching risk	High	Receives patients from older products
Revenue trajectory	Structural decline	Expansion, subject to saturation and competition
Patent value	Aging estate	Later-generation, higher-value estate
Generic risk	Increasing over time	More limited in the near term

Trikafta has largely captured the strategic value that Orkambi once held. Vertex’s objective is to preserve CFTR franchise revenue by moving patients from older regimens to the newest eligible treatment.

What is Orkambi’s financial exposure for Vertex?

Orkambi is no longer a major determinant of Vertex’s consolidated valuation. Its financial importance is now concentrated in three areas:

• Residual product revenue;
• Contribution margin from an established product;
• Portfolio and pricing effects in markets where patients remain on older therapy.

The product’s decline has been absorbed by the growth of Trikafta and Kaftrio. As a result, Orkambi revenue erosion does not translate one-for-one into Vertex-wide revenue loss.

The main financial risk is a faster-than-expected decline in the remaining patient base. That could result from:

• Expanded Trikafta labels;
• Better reimbursement for newer regimens;
• Physician preference for newer treatment;
• Additional evidence favoring Trikafta;
• Generic entry with substantial discounts;
• International price negotiations.

Orkambi’s residual revenue is more defensible in markets where newer treatments are unavailable or where payer restrictions delay switching. It is less defensible in the United States, where Trikafta is established as the central Vertex CF treatment.

What is the FDA regulatory status of Orkambi?

Orkambi remains an FDA-approved prescription medicine for eligible cystic fibrosis patients with the applicable CFTR mutation profile. Its regulatory status is not equivalent to commercial relevance. The product can remain approved and clinically useful while becoming financially immaterial.

The principal regulatory considerations are:

• Continued approval for labeled age groups and genotypes;
• Pediatric use and dosing;
• Labeling changes driven by safety or postmarketing data;
• Generic applications under the ANDA pathway;
• Therapeutic-equivalence determinations;
• Potential changes to treatment guidelines and payer coverage.

Key Takeaways

• Orkambi is a declining Vertex product, not a growth asset.
• Revenue fell from roughly $1 billion-plus at peak to approximately $100 million in 2024.
• The primary cause of decline is internal substitution by Trikafta and Kaftrio.
• Orkambi is a small-molecule product exposed to generic, not biosimilar, competition.
• Its patent protection includes compound, combination, formulation, method-of-use and manufacturing claims.
• Orange Book patents remain important for generic timing, but regulatory exclusivity has already expired.
• A generic launch would affect a residual market because most commercially valuable patients have moved to newer Vertex regimens.
• Orkambi’s remaining value is concentrated in treatment-constrained patients and international markets.
• The product’s financial decline has been offset by the expansion of Vertex’s broader CFTR franchise.

FAQs

Is Orkambi still commercially important to Vertex?

No. Orkambi remains an approved product with residual revenue, but Trikafta and Kaftrio now account for the economic center of Vertex’s cystic fibrosis business.

Can a generic version of Orkambi be approved?

Yes. Orkambi is a small-molecule drug eligible for an ANDA-based generic pathway, subject to bioequivalence requirements and resolution of applicable patent certifications.

Does Orkambi have biosimilar competition?

No. Biosimilar regulation applies to biologics. Orkambi would face generic competition or substitution by other small-molecule CFTR modulators.

Why do some patients remain on Orkambi?

Patients may remain on Orkambi because of age, genotype, tolerability, physician judgment, reimbursement restrictions, geographic access or inability to use newer CFTR combinations.

Does a generic Orkambi launch threaten Trikafta revenue?

The direct effect would likely be limited because Trikafta has already captured most eligible patients. The larger risk is incremental price pressure and faster erosion of the residual Orkambi business.

References

1. U.S. Food and Drug Administration. (2015). FDA approves new treatment for cystic fibrosis.
2. Vertex Pharmaceuticals Incorporated. (2016). 2016 annual report.
3. Vertex Pharmaceuticals Incorporated. (2019). 2019 annual report.
4. Vertex Pharmaceuticals Incorporated. (2021). 2021 annual report.
5. Vertex Pharmaceuticals Incorporated. (2024). 2024 annual report.
6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

DrugChatter Q&A for ORKAMBI

Orkambi manufacturers company?